PATENT CLAIM ANALYSIS

Application Number: 15986533
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "490000"]

Abstract:
The present disclosure relates to a to a method for treating peripheral neuropathy including diabetic neuropathy. It consists of comprehensive set of pain management medications such as sodium channel blockers, N-methyl-D-aspartate (NMDA) receptor antiagonists, α-2 adrenergic receptor agonists, anti-inflammatory drugs, calcium channel blockers, other classes of medications or their mixtures. The medical compound can be encapsulated in PLGA micro-particles for controlled, sustained release over 2-8 weeks. Once a doctor prescribes a set of pain management medications, the prescribed medication(s) can be administered individually or as their mixtures by a commercial painless or user-friendly micro-needle patch or injection device.

Claim (Index 7):
The medicament compound as recited in  claim 2 , wherein said compound is encircled by, and encapsulated within, a plurality of micro-particles that designed to have a controlled, sustained release of the medicaments over a period of 2-8 weeks.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.5
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13495657', '14048255', '14610780', '12664792', '11753419']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6734041270153261
- 35 USC 102 Novelty (BERT): 0.4826359302219002
- Combined Prediction Score: 0.6543273073359837
- Mean Citation Score: 158.672662
- Max Citation Score: 160.138
- Similarity Product: 116.50970478057864

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test